Table 3.
Relation between rifapentine daily dose, area under the concentration‐time curve from 0 to 24 h, and peak concentrationa
| Daily dose | No. of participants |
AUC0‐24
(μg × h/mL) |
Cmax
(μg/mL) |
||
|---|---|---|---|---|---|
| Dose (mg) | |||||
| 450 | 60 | 290 ± 123 | 255 (153, 510) | 14.7 ± 5.8 | 13.8 (8.2, 26.3) |
| 600 | 211 | 324 ± 143 | 295 (151, 579) | 17.0 ± 7.1 | 15.7 (7.7, 29.4) |
| 900 | 78 | 498 ± 149 | 503 (272, 721) | 25.1 ± 7.0 | 24.4 (13.8, 36.3) |
| 1200 | 30 | 587 ± 197 | 587 (317, 882) | 29.9 ± 9.1 | 31.4 (16.4, 43.1) |
| 1500 | 4 | 663 ± 84 | 666 (572, 748) | 33.2 ± 3.3 | 33.0 (29.8, 36.8) |
| Dose (mg/kg) | |||||
| 10 | 236 | 309 ± 132 | 285 (154, 570) | 16.1 ± 6.6 | 15.0 (7.86 27.8) |
| 15 | 74 | 434 ± 173 | 391 (203, 726) | 22.1 ± 8.2 | 20.5 (11.0, 35.7) |
| 20 | 73 | 546 ± 176 | 538 (290, 832) | 27.5 ± 8.2 | 28.0 (15.2, 40.4) |
AUC0‐24, area under the concentration‐time curve from 0 to 24 h; Cmax, peak concentration.
a
Data reported as mean ± SD or median (5th, 95th percentile).